Yanfang Xu 

Professor, Supervisor of Doctorate Candidates, Supervisor of Master's Candidates

Director of Center for Innovative Drug Research and Evaluation, 

Department of Pharmacology,

Hebei Medical University, 

050017, Shijiazhuang, Hebei, CHINA

E-mail: yanfangxu@hebmu.edu.cn

Education and Training

Postdoctoral Research Fellow at Internal Medicine Department, Division of Cardiovascular Medicine, University of Carlifornia (1999-2002)

Ph.D, Hebei Medical University (1995-1998)

M.D, Hebei Medical University (1979-1984)

Employment

Professor, Department of of Pharmacology, Hebei Medical University (2002-present)

Associate Professor, Department of of Pharmacology, Hebei Medical University (1989–1995)

Assistant Professor, Department of of Pharmacology, Hebei Medical University (1984–1986)

Research interests

The functional regulation and pathological remodeling of cardiac K+ channel so as to uncover novel antiarrhythmic targets.

Molecular mechanism underlying drug-induced cardiotoxicity and proarrhythmic risk evaluation for preclinical drug. 

Representative Publications in Recent 5 Years:

1.Zhang H, Zhang H, Wang C, Wang Y, Zou R, Shi C, Guan B, Gamper N, Xu Y. Auxiliary subunits control biophysical properties and response to compound NS5806 of the Kv4 potassium channel complex. FASEB J  2020 Jan; 34(1): 807-821. doi: 10.1096/fj.201902010RR. Epub 2019 Nov 27.

2.Li C, Zou R, Zhang H, Wang Y, Qiu B, Qiu S, Wang W, Xu Y. Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo. Arch Toxicol. 2019 Jun;93(6):1697-1712.

3.Shen L, Li C, Zhang H, Qiu S, Fu T, Xu Y. Downregulation of miR-146a Contributes to Cardiac Dysfunction Induced by the Tyrosine Kinase Inhibitor Sunitinib. Front Pharmacol. 2019 Aug 23;10:914. doi: 10.3389/fphar.2019.00914. eCollection 2019.

4.Qiu B, Wang Y, Li C, Guo H, Xu Y. Utility of the JT Peak Interval and the JT Area in Determining the Proarrhythmic Potential of QT-Shortening Agents. J Cardiovasc Pharmacol Ther. 2019; 24(2): 160-171.

5.Gou X, Wang W, Zou S, Qi Y, Xu Y.  Protein kinase C epsilon mediates the inhibition of angiotensin II on the slowly activating delayed-rectifier potassium current through channel phosphorylation. J Mol Cell Cardiol. 2018 Mar;116:165-174. 

6.Liu X, Wang Y, Zhang H, Shen L, Xu Y.  Different protein kinase C isoenzymes mediate inhibition of cardiac rapidly activating delayed rectifier K+ current by different G-protein coupled receptors. Br J Pharmacol. 2017 Dec;174(23):4464-4477. 

7.Lv Y, Bai S, Zhang H, Zhang H, Meng J, Li L, Xu Y. Aldosterone down-regulates the slowly activated delayed rectifier potassium current in adult guinea pig cardiomyocytes. Br J Pharmacol. 2015 Dec; 172(23): 5596–5608. 

8.Ma J, Zhang H, Guo H, Xu Y. Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats. Am J Transl Res 2014;6(6): 809-819.

9.Cai Y, Wang Y, Xu J, Zuo X, Xu Y. Down-regulation of Ether-a-go-go-Related Gene Potassium Channel Protein through Sustained Stimulation of AT1 Receptor by Angiotensin II. Biochem Biophys Res Commun. 2014 Sep 9. 452(3):852-7.